Exsure is transforming oncology care with its ExoDS platform, designed to deliver chemotherapy drugs directly to tumor cells while sparing healthy tissue. This breakthrough reduces toxicity by 70%, enhances treatment outcomes, and effectively targets drug-resistant cancer stem cells. By addressing significant challenges like drug toxicity and cancer relapse, Exsure is setting a new benchmark in cancer therapy. With innovative products, ongoing non-clinical studies, and selection into the OIST Innovation Accelerator program in Japan to drive business expansion and clinical trials, Exsure is paving the way for safer, more effective cancer treatments and global impact in oncology care.

exsure.in